Rare ashy dermatosis‐like hyperpigmentation associated with osimertinib

Autor:	Kazuhito Funai
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	ashy dermatosis‐like hyperpigmentation dermatological adverse event epidermal growth factor receptor‐tyrosine kinase inhibitor lung adenocarcinoma quality of life Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Thoracic Cancer, Vol 13, Iss 9, Pp 1436-1437 (2022)
Druh dokumentu:	article
ISSN:	1759-7714 1759-7706
DOI:	10.1111/1759-7714.14383
Popis:	Abstract Osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR‐TKI and is widely used as the first‐line treatment for EGFR mutation‐positive non‐small cell lung cancer. Pigmentary changes caused by EGFR‐TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin‐related adverse event. Here, I report a case of osimertinib‐associated ashy dermatosis‐like hyperpigmentation on imaging. Although reducing the dose of osimertinib to 40 mg did not improve pigmentation, osimertinib use was continued due to its clinical and radiological benefit, which persisted for a long time.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/a8d117388623481a8f884cb6693b04b7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.